IL1B and type 2 diabetes mellitus: Recombinant mutated IL-1β chemically cross-linked to bacteriophage Qβ VLPs (hIL1βQβ) was investigated in a phase 1 clinical trial for T2DM resulting in safe production of specific IL-1β antibodies in the treated patients (Cavelti-Weder et al., 2016).